SageView Advisory Group LLC Invests $271,000 in Novo Nordisk A/S (NYSE:NVO)

SageView Advisory Group LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,489 shares of the company’s stock, valued at approximately $271,000.

Several other hedge funds also recently bought and sold shares of NVO. Pacific Center for Financial Services lifted its position in shares of Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares in the last quarter. CNB Bank purchased a new position in Novo Nordisk A/S in the 4th quarter worth approximately $26,000. Tyler Stone Wealth Management boosted its stake in Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after purchasing an additional 146 shares during the period. West Paces Advisors Inc. grew its holdings in Novo Nordisk A/S by 100.0% during the 3rd quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock valued at $27,000 after buying an additional 150 shares in the last quarter. Finally, Valued Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $28,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on NVO shares. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a research report on Thursday, May 30th. They set a “buy” rating and a $156.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday. BMO Capital Markets began coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 price target for the company. Finally, Argus lifted their price objective on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average price target of $145.67.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $140.99 on Friday. The company has a market cap of $632.70 billion, a P/E ratio of 48.62, a P/E/G ratio of 1.40 and a beta of 0.41. The business’s 50 day moving average price is $132.60 and its 200-day moving average price is $121.44. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $144.50. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. The business had revenue of $9.52 billion for the quarter, compared to analysts’ expectations of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. Sell-side analysts predict that Novo Nordisk A/S will post 3.41 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.